New Clues that May Link Osteoporosis to the Circulating Lipid Profile

Abstract

Bone Mineral Density (BMD) is a gold standard for the diagnosis of osteoporosis and is also important in the assessment of fracture risk. Other risk factors have been identified that together make up fracture risk assessment tools such as FRAX. Another potential factor, circulating lipids, has been suggested because of reports linking statins to fracture risk reduction. We analyzed the lipid profile in a cohort of women diagnosed with postmenopausal osteoporosis based on bone density determination: 610 women with osteoporosis (mean lumbar spine T-score −3.16±0.81, mean yrs. since menopause 15.79±8.9) were grouped according to age at evaluation (< 50 years, 51–60 years, 61–70 years, > 70 years), the presence/absence of a history of a fragility fracture, statin and/or antiresorptive drug use. There was no correlation between BMD and Body Mass Index (BMI: P>0.05, r ²<0.02). However, when BMD was correlated with both BMI and the lipid profile (Triglycerides, Cholesterol, LDLc, HDLc), significant correlations were found in 5 cohorts: 51–60 years with fractures (n=61, r ²=0.14, P<0.01), 61–70 years (n=201, r ²=0.09, P<0.01) with fractures (n=88, r ²=0.14, P<0.01) or without fractures (n=113, r ²=0.24, P=0.02) and over 70 years (n=247, r ²=0.11, P<0.01).

References

[1] Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science, 1999, 286: 1946-1949

[2] Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A, 1999, 96: 133-138

[3] Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol, 2011, 8: 81-91

[4] Cruz AC, Gruber BL. Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleve Clin J Med, 2002, 69: 277-278

[5] Huang W, Shang WL, Li DH, Wu WW, Hou SX. Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4. Mol Cell Biochem, 2012, 360: 71-77

[6] Tanriverdi HA, Barut A, Sarikaya S. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Epidemiol, 2004, 19: 1105-1112

[7] Lupattelli G, Scarponi AM, Vaudo G, Siepi D, Roscini AR, Gemelli F, Pirro M, Latini RA, Sinzinger H, Marchesi S, Mannarino E. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism, 2004, 53: 744-748

[8] Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med, 2004, 164: 146-152

[9] Bakhireva LN, Shainline MR, Carter S, Robinson S, Beaton SJ, Nawarskas JJ, Gunter MJ. Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. Pharmacotherapy, 2010, 30: 879-887

[10] Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, Lucani B, Gennari C. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone, 2003, 32: 427-433

[11] Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet, 2000, 355: 2185-2188

[12] LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley SG, Passaro MD, Jackson RD. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med, 2003, 139: 97-104

[13] Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab, 2001, 86: 4556-4559

[14] Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses, 2011, 76: 317-321

[15] Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Stefanadis C, Papavassiliou AG. Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr Pharm Des, 2011, 17: 4132-4146

[16] Kvasnicka T, Kvasnicka J, Ceska R, Vrablik M. Increase of inflammatory state in overweight adults with combined hyperlipidemia. Nutr Metab Cardiovasc Dis, 2003, 13: 227-231

[17] Sage AP, Lu J, Atti E, Tetradis S, Ascenzi MG, Adams DJ, Demer LL, Tintut Y. Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids. J Bone Miner Res, 2011, 26: 1197-1206

[18] Tarakida A, Iino K, Abe K, Taniguchi R, Higuchi T, Mizunuma H, Nakaji S. Hypercholesterolemia accelerates bone loss in postmenpausal women. Climacteric, 2011, 14: 105-111

[19] Yamaguchi T. Bone metabolism in dyslipidemia and metabolic syndrome. Clin Calcium, 2011, 21: 677-682

[20] Tintut Y, Morony S, Demer LL. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler Thromb Vasc Biol, 2004, 24: e6-e10

[21] Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K. Increased bone turnover in patients with hypercholesterolemia. Endocr J, 2008, 55: 143-151

[22] Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol, 2004, 19: 1105-1112

[23] National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center. Bone Mass Measurement: What the numbers mean [internet] May 2009 [cited June 2013].

[24] Makovey J, Chen JS, Hayward C, Williams FM, Sambrook PN. Association between serum cholesterol and bone mineral density. Bone, 2009, 44: 208-213

[25] Tankó LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women? Bone, 2003, 32: 8-14

[26] Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke, 1997, 28: 1730-1732

[27] Samelson EJ, Cupples LA, Hannan MT, Wilson PW, Williams SA, Vaccarino V, Zhang Y, Kiel DP. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. Bone, 2005, 34: 557-561

[28] Solomon DH, Avorn J, Canning CF, Wang PS. Lipid levels and bone mineral density. Am J Med, 2005, 118: 1414

[29] Wu LY, Yang TC, Kuo SW, Hsiao CF, Hung YJ, Hsieh CH, Tseng HC, Hsieh AT, Chen TW, Chang JB, Pei D. Correlation between bone mineral density and plasma lipids in Taiwan. Endocr Res, 2003, 29: 317-325

[30] Ackert-Bicknell CL. HDL cholesterol and bone mineral density: is there a genetic link? Bone, 2012, 50: 525-533

[31] Karasik D, Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone, 2010, 46: 1226-1237

[32] Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci, 2000, 908: 244-254

[33] Koshiyama H, Ogawa Y, Tanaka K, Tanaka I. The unified hypothesis of interactions among the bone, adipose and vascular systems: ‘osteo-lipo-vascular interactions’. Med Hypotheses, 2006, 66: 960-963